Jeremy Norris (Presenter)
Vanderbilt University School of Medicine
Bio: Jeremy L. Norris earned his B.S in Chemistry from the University of Tennessee in 1998 and his Ph.D. in Chemistry from Vanderbilt University in 2003 and has been working professionally in mass spectrometry, separation science, and organic chemistry since that time. Until 2011, Dr. Norris was Vice President of Research and Development at Protein Discovery, Inc. During his 6 year tenure at Protein Discovery, Dr. Norris developed and commercialized for than 12 sample preparation products, including 2 instruments for preparative electrophoresis, and operated a fee-for-service laboratory specializing in imaging mass spectrometry. Dr. Norris returned to Vanderbilt University in 2011 where he is currently Associate Professor in the Departments of Biochemistry and Chemistry and is the Managing Director of the National Resource for Imaging Mass Spectrometry.
Authorship: Jeremy L. Norris
Vanderbilt University School of Medicine
| Short Abstract Mass spectrometry technologies have advanced significantly, allowing for sensitive and specific measurements of drugs as well as their impact on biological systems. Current instrumentation and methodologies in imaging mass spectrometry now allow for the study of biology at the cellular level, the tissue level, and the level of a whole organism. These capabilities provide the opportunity for molecular understanding about complex drugs mechanisms and interactions that have not previously been available to drug developers. This presentation overviews these advances, provides example of their use, and discusses the prospects for transitioning these technologies to aid in drug development. |
Long Abstract
Mass spectrometry technologies have advanced significantly, allowing for sensitive and specific measurements of drugs as well as their impact on biological systems. Current instrumentation and methodologies in imaging mass spectrometry now allow for the study of biology at the cellular level, the tissue level, and the level of a whole organism. These capabilities provide the opportunity for molecular understanding about complex drugs mechanisms and interactions that have not previously been available to drug developers. This presentation overviews these advances, provides example of their use, and discusses the prospects for transitioning these technologies to aid in drug development.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | no | |
| Salary | no | |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |